Downloads: 0 | Views: 41
Informative Article | Pharmacotherapeutics | India | Volume 11 Issue 6, June 2022
Will Dostarlimab Become the New Rectal Cancer Drug of Choice?
Abstract: Information on a recent clinical trial in the United States on a drug that has been shown to be nearly 100% effective against rectal cancer in the sample population.
Keywords: Dostarlimab, Rectal cancer, new drug of choice
Edition: Volume 11 Issue 6, June 2022,
Pages: 1369 - 1369